Senseonics Announces Favorable Outcome of FDA Advisory Committee on the Eversense System

By |2018-06-21T14:59:24+00:00April 2nd, 2018|CGM, Senseonics|

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. [...]

Senseonics Advanced CGM Technology in the News

By |2017-11-16T15:54:40+00:00November 20th, 2017|CGM, Science & Technology|

The 17th Annual Diabetes Technology Meeting in Bethesda, MD earlier this month highlighted important technological and scientific advances for the management of diabetes. Senseonics Director of R&D, Dr. Andrew DeHennis was invited to participate in the panel discussion on Advances in Continuous Glucose Monitoring. As the only panel member from a company with an implantable, [...]

David Edelman visited Senseonics

By |2017-12-04T17:03:24+00:00November 14th, 2017|CGM, Senseonics|

Senseonics welcomed David Edelman from Diabetes Daily yesterday. David gave a great presentation on the importance of peer support communities for people with diabetes and their care allies. Also discussed was Senseonics’ advanced CGM technology and how it is designed to transform the CGM user experience. David talked about the importance of CGM and its [...]

What is CGM?

By |2017-12-04T16:51:24+00:00November 13th, 2016|CGM|

Continuous Glucose Monitoring, or CGM, is the process of measuring the amount of sugar (glucose) in your body every few minutes through a sensor that is placed under your skin. The continuous readings allow the system to use the data to predict the direction your glucose level is heading and will display that information as [...]